The CD15 #Immunohistochemical Marker of #Hodgkin-Reed-Sternberg cells - a Perspective by Daniel Benharroch in BJSTR

Abstract

A historical perspective of the expression of CD15 in classic #Hodgkinlymphoma is presented. CD15 antigens expression has ranged over the years from 27% to 90% and more. The CD15 expression, although showing a sensitivity and specificity of less than 90% for #Hodgkin-Reed-Sternberg (HRS) cells [1], has been used for several decades, together with CD30 to confirm the#diagnosis of the presently classified classic Hodgkin lymphoma (cHL). Historically, the #tumorcells of this #malignancy have been considered to express from 75 to 90% positivity for this marker, using manual #immunophenotyping and non-sialyl-CD15 antibodies [2]. This variance might have been due in part to the fixation process (stronger staining with the B5 fixation when compared with neutral formalin); and in part due to the anti-CD15 #antibody employed (LeuM1 - Becton Dickinson; 80H5 - Immunotech, Marseille; C3D1 clone, DakoM1 - Dakopatts and others - the classic anti-CD15 antibodies). When the automated stainer, Ventana Benchmark (Ventana Medical Systems, Tucson, AZ), was introduced around 2009, some noted that the usual CD15 antibodies showed a much reduced staining capacity, and the HRS cells positivity in some labs reached an all times low of around 40%.

For more Biomedical open access journals please click on https://biomedres.us/

For more Research Articles on BJSTR

https://biomedres.us/abstracts/BJSTR.MS.ID.000912.php 

https://biomedres.us/fulltexts/BJSTR.MS.ID.000912.php 

The CD15 #Immunohistochemical Marker of #Hodgkin-Reed-Sternberg cells - a Perspective by Daniel Benharroch in BJSTR